Charles Schwab’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Charles Schwab’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-752	Closed	-$2.26K	–	3543
2023 Q3	$2.26K	Hold	752	–	–	﹤0.01%	3574
2023 Q2	$23.3K	Hold	752	–	–	﹤0.01%	3541
2023 Q1	$37.2K	Hold	752	–	–	﹤0.01%	3401
2022 Q4	$18.5K	Hold	752	–	–	﹤0.01%	3510
2022 Q3	$50K	Hold	752	–	–	﹤0.01%	3328
2022 Q2	$32K	Hold	752	–	–	﹤0.01%	3456
2022 Q1	$38K	Hold	752	–	–	﹤0.01%	3556
2021 Q4	$46K	Hold	752	–	–	﹤0.01%	3522
2021 Q3	$38K	Hold	752	–	–	﹤0.01%	3476
2021 Q2	$43K	Sell	752 -4,456	-86%	-$238K	﹤0.01%	3390
2021 Q1	$300K	Buy	5,208 +859	+20%	+$64.9K	﹤0.01%	3243
2020 Q4	$296K	Sell	4,349 -357	-8%	-$48.6K	﹤0.01%	3166
2020 Q3	$1.2M	Buy	4,706 +121	+3%	+$24.8K	﹤0.01%	2636
2020 Q2	$772K	Buy	4,585 +3,833	+510%	+$413K	﹤0.01%	2700
2020 Q1	$53K	Hold	752	–	–	﹤0.01%	3152
2019 Q4	$49K	Hold	752	–	–	﹤0.01%	3122
2019 Q3	$45K	Hold	752	–	–	﹤0.01%	3124
2019 Q2	$45K	Hold	752	–	–	﹤0.01%	3156
2019 Q1	$49K	Buy	+752	New	+$42.8K	﹤0.01%	3132

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LWM

Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Charles Schwab's BCLI Position: Q4 2023 in Review

Charles Schwab sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 752 shares — an estimated $2.26K sold.

Charles Schwab first reported a position in BCLI in Q1 2019 and held it in 19 quarters. The position peaked at $1.2M in Q3 2020. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

Charles Schwab reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
Charles Schwab sold 752 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $2.26K.
Charles Schwab first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2019 and held it in 19 quarters.
Charles Schwab's BRAINSTORM CELL THERAPUTC position peaked at $1.2M in Q3 2020.
46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Charles Schwab's 13F filing for Q4 2023, filed 6 Feb 2024.